Autres langues Phathom Pharmaceuticals, Inc.

Actions

PHAT

US71722W1071

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
9,42 ^USD	-7,56 %		-10,29 %	+3,18 %

09/05	Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Phathom Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
PHATHOM PHARMACEUTICALS, INC. : Stifel Nicolaus maintient sa recommandation à l'achat	03/05
Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Phathom Pharmaceuticals Announces Voquezna® Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	13/02
PHATHOM PHARMACEUTICALS, INC. : Needham & Co. persiste à l'achat	05/01
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	06/12
Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? Tablets	28/11
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Phathom Pharmaceuticals Insider Sold Shares Worth $110,871, According to a Recent SEC Filing	03/11
PHATHOM PHARMACEUTICALS, INC. : Goldman Sachs maintient sa recommandation neutre	03/11
Transcript : Phathom Pharmaceuticals, Inc. - Special Call	02/11
Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults	01/11
Phathom Pharmaceuticals Says US FDA Approves Reformulation of Vonoprazan Tablets for Helicobacter Pylori Infection	30/10/23
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults	30/10/23
Phathom Pharmaceuticals Seeks FDA Nod for Vonoprazan to Treat Non-Erosive GERD in Adults	26/09/23
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany	26/09/23
Sector Update: Health Care Stocks Gaining Late Afternoon	21/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Phathom Pharmaceuticals, Inc.

Actions

PHAT

US71722W1071

Autres langues

Filtres